Clinical Significance Of Serum Vascular Endothelial Growth Factor And Interleukin-17 In Patients With Diffuse Large B Cell Lymphoma

Objective: Serum vascular endothelial growth factor(VEGF)and interleukin-17(IL-17)in patients with diffuse large B-cell lymphoma(DLBCL)were measured and their correlation with clinical features were analyzed,to explore the roles of them in the occurrence,development,invasion and metastasis of DLBCL,and to provide more experimental and clinical theoretical basis for novel prognostic index and immunotherapy for DLBCL.Methods: A total of 60 patients with newly diagnosed diffuse large B-cell lymphoma admitted to Shaoyang Central Hospital of Hunan Province from Jan.2016 to Feb.2018 were enrolled,and 60 volunteers undergoing health examination over the same period were included as control.Serum levels of VEGF and IL-17 in patients of each group were determined by enzyme-linked immune sorbent assay(ELISA),and the serum IL-17 levels of patients were determined by cytometric bead array(CBA).The DLBCL patients were treated according to the NCCN clinical practice guidelines of 2015.After four courses of treatment,the serum VEGF and IL-17 levels of each DLBCL patient were measured again,and compared with the values before treatment.The four sets of data were analyzed to reveal the correlation of serum VEGF and IL-17 levels to DLBCL.Furthermore,the patients with DLBCL were stratified according to different IPI score,gender,and B symptoms,the serum levels of VEGF and IL-17 were compared among these subgroups.SPSS 20 statistical software was used for data analysis.Results:(1)Expression of serum VEGF in patients with DLBCL was significantly higher compared than in the healthy subjects,and IL-17 was just the opposite(P<0.05).(2)Serum VEGF in patients with DLBCL significantly decreased after four courses of treatment,and the expression levels of IL-17 was statistically increased than before(P<0.05).(3)Expressions of serum VEGF and IL-17 in DLBCL patients were negatively correlated(correlation coefficient r=?0.695,P<0.01).(4)Serum VEGF level in patients with DLBCL was significantly correlated with IPI score,Ann Arbor stage,number of extranodal sites and B symptoms(P<0.05),but not with the age,gender,ECOG PS score and serum LDH level(P>0.05).Serum IL-17 level in patients with DLBCL was significantly correlated with IPI score,Ann Arbor stage,age,ECOG PS score and B symptoms(P<0.05),but not with the gender,number of extranodal sites and serum LDH level(P>0.05).With the increase of IPI score,the serum expression of VEGF increased and the IL-17 was just the opposite.(5)In DLBCL patients,the serum levels of VEGF in the patients with effective chemotherapy were significantly lower than in those who had no effect of chemotherapy,and the levels of IL-17 were just the opposite.However,there was no significant difference between VEGF and IL-17 before and after treatment in patients with ineffective chemotherapy.Conclusions:(1)Serum VEGF levels are increased in patients with DLBCL,and serum IL-17 of them are decreased,and are related to the IPI score and therapeutic effect of DLBCL,which is of significance in the prognosis and effectiveness observation of DLBCL.(2)The negative correlation between the expression of serum VEGF and IL-17 in patients with DLBCL suggests that there may be a negative regulatory mechanism between the two.